Marko Skelin

641 total citations
25 papers, 270 citations indexed

About

Marko Skelin is a scholar working on Molecular Biology, Genetics and Hematology. According to data from OpenAlex, Marko Skelin has authored 25 papers receiving a total of 270 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Genetics and 5 papers in Hematology. Recurrent topics in Marko Skelin's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers), Eosinophilic Disorders and Syndromes (3 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Marko Skelin is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers), Eosinophilic Disorders and Syndromes (3 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Marko Skelin collaborates with scholars based in Croatia, United States and Ireland. Marko Skelin's co-authors include Tomo Lucijanić, Dario Rahelić, Marko Lucijanić, Hossein Gharib, Daniela Amidžić Klarić, Rajko Kušec, Ivica Lukšić, Tajana Štoos‐Veić, Vlatko Pejša and Ivan Krečak and has published in prestigious journals such as Annals of Oncology, International Journal of Cardiology and Clinical Therapeutics.

In The Last Decade

Marko Skelin

22 papers receiving 262 citations

Peers

Marko Skelin

EDM

GENET

SURGE

ONCOL

Mitsuru Ichii Japan

Robert Puckrin Canada

Renata Świątkowska−Stodulska Poland

Francesco Logoluso Italy

Laura Rivoli Italy

Abdallah Sassine Geara United States

Vasil Peev United States

Gianluca Usala Italy

Matthias Schuetz Austria

Florian G. Scurt Germany

Mitsuru Ichii Japan

Marko Skelin

59 ×0.7

EDM

26 ×0.5

GENET

43 ×1.0

SURGE

30 ×0.8

ONCOL

Citations per year, relative to Marko Skelin Marko Skelin (= 1×) peers Mitsuru Ichii

Countries citing papers authored by Marko Skelin

Since Specialization

Citations

This map shows the geographic impact of Marko Skelin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marko Skelin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marko Skelin more than expected).

Fields of papers citing papers by Marko Skelin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marko Skelin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marko Skelin. The network helps show where Marko Skelin may publish in the future.

Co-authorship network of co-authors of Marko Skelin

This figure shows the co-authorship network connecting the top 25 collaborators of Marko Skelin. A scholar is included among the top collaborators of Marko Skelin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marko Skelin. Marko Skelin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Krečak, Ivan, et al.. (2025). High lymphocyte count and bleeding risk in patients with chronic lymphocytic leukemia treated with Bruton’s tyrosine kinase inhibitors. Wiener klinische Wochenschrift. 137(21-22). 702–706. 1 indexed citations

Krečak, Ivan, et al.. (2024). Diabetes mellitus, metformin, and the risk of MPN. Blood Advances. 8(22). 5929–5931. 1 indexed citations

Krečak, Ivan, et al.. (2024). Prolonged Proton Pump Inhibitor Use and Thrombohemorrhagic Risk in Essential Thrombocythemia and Polycythemia Vera Patients Treated with Long-Term Aspirin: A Pilot Study. Pharmacology. 109(2). 110–114.

Krečak, Ivan, et al.. (2024). No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study. Heliyon. 10(12). e32827–e32827.

Skelin, Marko, et al.. (2024). Levels of evidence and grades of recommendation supporting European society for medical oncology clinical practice guidelines. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 32(5). 807–815.

Krečak, Ivan, Marko Skelin, & Srđan Verstovšek. (2023). Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera. Expert Review of Hematology. 16(5). 305–316. 5 indexed citations

Krečak, Ivan, et al.. (2023). Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms. Biomedicines. 11(5). 1301–1301. 5 indexed citations

Krečak, Ivan, et al.. (2022). Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim. Transfusion and Apheresis Science. 62(2). 103582–103582. 1 indexed citations

Krečak, Ivan, et al.. (2022). Scurvy.. PubMed. 30(1). 59–60. 1 indexed citations

10.

Skelin, Marko, et al.. (2022). The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis. Journal of Chemotherapy. 35(2). 150–157. 6 indexed citations

11.

Skelin, Marko, et al.. (2021). The economic impact of a clinical pharmacist’s involvement in the hospital medicines policy in a rural area. International Journal of Clinical Practice. 75(11). e14859–e14859. 1 indexed citations

12.

Skelin, Marko, et al.. (2021). De-escalation in HPV-associated oropharyngeal cancer: lessons learned from the past? A critical viewpoint and proposal for future research. European Archives of Oto-Rhino-Laryngology. 278(11). 4599–4603. 7 indexed citations

13.

Rahelić, Dario, et al.. (2020). Recommendations of the Working group of the Croatian Society for Diabetes and Metabolic Disorders of the Croatian Medical Association for people with diabetes and healthcare professionals in the Republic of Croatia during COVID-19 pandemic. University of Zagreb University Computing Centre (SRCE). 142(3-4). 1 indexed citations

14.

Lucijanić, Marko, et al.. (2019). Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes. International Journal of Cardiology. 301. 90–95. 21 indexed citations

15.

Skelin, Marko, et al.. (2019). Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE. European Archives of Oto-Rhino-Laryngology. 276(5). 1275–1281. 11 indexed citations

16.

Skelin, Marko, Tomo Lucijanić, Sanja Klobučar Majanović, et al.. (2018). Effect of timing of levothyroxine administration on the treatment of hypothyroidism: a three-period crossover randomized study. Endocrine. 62(2). 432–439. 21 indexed citations

17.

Lucijanić, Marko, Dario Rahelić, Vlatko Pejša, et al.. (2018). Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis. Wiener klinische Wochenschrift. 130(3-4). 126–133. 30 indexed citations

18.

Lucijanić, Marko, et al.. (2018). Elevated Neutrophil–to–Lymphocyte-ratio and Platelet–to–Lymphocyte Ratio in Myelofibrosis: Inflammatory Biomarkers or Representatives of Myeloproliferation Itself?. Anticancer Research. 38(5). 3157–3163. 28 indexed citations

19.

Lucijanić, Marko, Marko Skelin, & Tomo Lucijanić. (2017). Survival analysis, more than meets the eye. Biochemia Medica. 27(1). 14–18. 20 indexed citations

20.

Skelin, Marko, et al.. (2017). Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review. Clinical Therapeutics. 39(2). 378–403. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact